GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Days Sales Outstanding

ProSomnus (ProSomnus) Days Sales Outstanding : 42.39 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Days Sales Outstanding?

ProSomnus's average Accounts Receivable for the three months ended in Dec. 2023 was $3.64 Mil. ProSomnus's Revenue for the three months ended in Dec. 2023 was $7.84 Mil. Hence, ProSomnus's Days Sales Outstanding for the three months ended in Dec. 2023 was 42.39.

The historical rank and industry rank for ProSomnus's Days Sales Outstanding or its related term are showing as below:

OSAPQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.16   Med: 46.32   Max: 64.27
Current: 43.16

During the past 4 years, ProSomnus's highest Days Sales Outstanding was 64.27. The lowest was 43.16. And the median was 46.32.

OSAPQ's Days Sales Outstanding is ranked better than
80.07% of 808 companies
in the Medical Devices & Instruments industry
Industry Median: 64.065 vs OSAPQ: 43.16

ProSomnus's Days Sales Outstanding increased from Dec. 2022 (40.84) to Dec. 2023 (42.39).


ProSomnus Days Sales Outstanding Historical Data

The historical data trend for ProSomnus's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Days Sales Outstanding Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
64.27 46.13 46.51 44.10

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.84 43.25 40.95 45.19 42.39

Competitive Comparison of ProSomnus's Days Sales Outstanding

For the Medical Devices subindustry, ProSomnus's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProSomnus's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where ProSomnus's Days Sales Outstanding falls into.



ProSomnus Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

ProSomnus's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.843 + 3.839) / 2 ) / 27.652*365
=3.341 / 27.652*365
=44.10

ProSomnus's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (3.443 + 3.839) / 2 ) / 7.838*365 / 4
=3.641 / 7.838*365 / 4
=42.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProSomnus  (OTCPK:OSAPQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


ProSomnus Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of ProSomnus's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


ProSomnus (ProSomnus) Business Description

Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073